Genelux Corp (GNLX)
2.39
+0.03
(+1.27%)
USD |
NASDAQ |
Jun 17, 16:00
2.39
0.00 (0.00%)
Pre-Market: 09:24
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 64.52M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -93.17% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 4.278 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others. |
URL | https://www.genelux.com |
Investor Relations URL | https://investors.genelux.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Aug. 14, 2024 (est.) |
Last Earnings Release | May. 09, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others. |
URL | https://www.genelux.com |
Investor Relations URL | https://investors.genelux.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Aug. 14, 2024 (est.) |
Last Earnings Release | May. 09, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |